Literature DB >> 16183649

Accumulation of mutant alpha1-antitrypsin Z in the endoplasmic reticulum activates caspases-4 and -12, NFkappaB, and BAP31 but not the unfolded protein response.

Tunda Hidvegi1, Bela Z Schmidt, Pamela Hale, David H Perlmutter.   

Abstract

In alpha(1)-antitrypsin (alpha1AT) deficiency, a polymerogenic mutant form of the secretory glycoprotein alpha1AT, alpha1ATZ, is retained in the endoplasmic reticulum (ER) of liver cells. It is not yet known how this results in liver injury in a subgroup of deficient individuals and how the remainder of deficient individuals escapes liver disease. One possible explanation is that the "susceptible" subgroup is unable to mount the appropriate protective cellular responses. Here we examined the effect of mutant alpha1ATZ on several potential protective signaling pathways by using cell lines with inducible expression of mutant alpha1AT as well as liver from transgenic mice with liver-specific inducible expression of mutant alpha1AT. The results show that ER retention of polymerogenic mutant alpha1ATZ does not result in an unfolded protein response (UPR). The UPR can be induced in the presence of alpha1ATZ by tunicamycin excluding the possibility that the pathway has been disabled. In striking contrast, ER retention of nonpolymerogenic alpha1AT mutants does induce the UPR. These results indicate that the machinery responsible for activation of the UPR can distinguish the physical characteristics of proteins that accumulate in the ER in such a way that it can respond to misfolded but not relatively ordered polymeric structures. Accumulation of mutant alpha1ATZ does activate specific signaling pathways, including caspase-12 in mouse, caspase-4 in human, NFkappaB, and BAP31, a profile that was distinct from that activated by nonpolymerogenic alpha1AT mutants.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16183649     DOI: 10.1074/jbc.M508652200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  94 in total

Review 1.  Autophagy: a primer for the gastroenterologist/hepatologist.

Authors:  Christiane Sokollik; Michelle Ang; Nicola Jones
Journal:  Can J Gastroenterol       Date:  2011-12       Impact factor: 3.522

Review 2.  Novel treatment strategies for liver disease due to α1-antitrypsin deficiency.

Authors:  Nicholas Maurice; David H Perlmutter
Journal:  Clin Transl Sci       Date:  2012-01-10       Impact factor: 4.689

3.  Defining the mechanism of polymerization in the serpinopathies.

Authors:  Ugo I Ekeowa; Joanna Freeke; Elena Miranda; Bibek Gooptu; Matthew F Bush; Juan Pérez; Jeff Teckman; Carol V Robinson; David A Lomas
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-20       Impact factor: 11.205

Review 4.  Proinsulin misfolding and diabetes: mutant INS gene-induced diabetes of youth.

Authors:  Ming Liu; Israel Hodish; Leena Haataja; Roberto Lara-Lemus; Gautam Rajpal; Jordan Wright; Peter Arvan
Journal:  Trends Endocrinol Metab       Date:  2010-08-18       Impact factor: 12.015

Review 5.  Alpha-1 Antitrypsin Deficiency-Mediated Liver Toxicity: Why Do Some Patients Do Poorly? What Do We Know So Far?

Authors:  Marion Bouchecareilh
Journal:  Chronic Obstr Pulm Dis       Date:  2020-07

6.  Hepatic progenitor cell proliferation and liver injury in α-1-antitrypsin deficiency.

Authors:  Elizabeth M Brunt; Keith Blomenkamp; Muneeb Ahmed; Faiza Ali; Nancy Marcus; Jeffrey Teckman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-11       Impact factor: 2.839

Review 7.  Gene therapy for alpha-1 antitrypsin deficiency.

Authors:  Terence R Flotte; Christian Mueller
Journal:  Hum Mol Genet       Date:  2011-04-16       Impact factor: 6.150

8.  Sequestration of mutated alpha1-antitrypsin into inclusion bodies is a cell-protective mechanism to maintain endoplasmic reticulum function.

Authors:  Susana Granell; Giovanna Baldini; Sameer Mohammad; Vanessa Nicolin; Paola Narducci; Brian Storrie; Giulia Baldini
Journal:  Mol Biol Cell       Date:  2007-11-28       Impact factor: 4.138

Review 9.  Protein misfolding and the serpinopathies.

Authors:  Didier Belorgey; Peter Hägglöf; Susanna Karlsson-Li; David A Lomas
Journal:  Prion       Date:  2007-01-06       Impact factor: 3.931

Review 10.  Barriers to inhaled gene therapy of obstructive lung diseases: A review.

Authors:  Namho Kim; Gregg A Duncan; Justin Hanes; Jung Soo Suk
Journal:  J Control Release       Date:  2016-05-16       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.